ClinicalTrials.gov record
Not yet recruiting Phase 2 Interventional

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

ClinicalTrials.gov ID: NCT06732245

Public ClinicalTrials.gov record NCT06732245. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women

Study identification

NCT ID
NCT06732245
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Biomed Industries, Inc.
Industry
Enrollment
224 participants

Conditions and interventions

Interventions

  • NA-931 Drug
  • NA-931 150 mg + no Tirzepatide Drug
  • Tirzepatide Drug

Drug

Eligibility (public fields only)

Age range
19 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 14, 2026
Primary completion
Aug 14, 2027
Completion
Dec 14, 2027
Last update posted
Mar 26, 2026

2026 – 2027

United States locations

U.S. sites
8
U.S. states
4
U.S. cities
8
Facility City State ZIP Site status
Biomed Research Unit #90067-102 Los Angeles California 90067
Biomed Research Unit # 92121-103 San Diego California 92121
Biomed Research Unit # 94104-101 San Francisco California 94104
Biomed Research Unit # 33012-104 Hialeah Florida 33012
Biomed Research Unit # 32256-105 Jacksonville Florida 32256
Biomed Research Unit # 33461-106 Lake Worth Florida 33461
Biomed Research Unit # 10021-107 New York New York 10021
Biomed Research Unit # 77479-108 Sugar Land Texas 77479

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06732245, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 26, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06732245 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →